185 related articles for article (PubMed ID: 32749499)
1. [Indications and results of radioiodine treatment of differentiated thyroid cancer].
Riemann B
Chirurg; 2020 Dec; 91(12):1013-1016. PubMed ID: 32749499
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
[TBL] [Abstract][Full Text] [Related]
4. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
5. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
6. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
7. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
9. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
Patel SS; Goldfarb M
J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
[TBL] [Abstract][Full Text] [Related]
10. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699
[TBL] [Abstract][Full Text] [Related]
11. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
12. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
[TBL] [Abstract][Full Text] [Related]
13. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
15. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
16. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine.
Chow SM; Law SC; Mendenhall WM; Au SK; Yau S; Mang O; Lau WH
Pediatr Blood Cancer; 2004 Feb; 42(2):176-83. PubMed ID: 14752883
[TBL] [Abstract][Full Text] [Related]
17. Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B; Menhart K; Hellwig D; Grosse J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629126
[TBL] [Abstract][Full Text] [Related]
18. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?
Kiernan CM; Parikh AA; Parks LL; Solórzano CC
J Am Coll Surg; 2015 Apr; 220(4):617-25. PubMed ID: 25667136
[TBL] [Abstract][Full Text] [Related]
19. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
20. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
